Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Skin of Color Psoriasis
NCT04571567Phase 4Completed
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in plaque psoriasis. Primary endpoint: Change in Psoriasis Area Severity Index 90 at Week 24. Started Dec 2019; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04571567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571567.